JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

JenaValve Technology, Inc. IRVINE, Calif. and CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

(MENAFN- GlobeNewsWire - Nasdaq) IRVINE, Calif. and CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve ...

IRVINE, Calif. and CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Bouffant caps, beard covers, and more—the idea is to prevent infection. Some say the requirements are overkill.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Rising prevalence of cardiovascular diseases and rapid advancements in minimally invasive procedures are fueling the growth of the Heart Valve Devices Market. Valued at US$ 10.9 billion in 2023, the ...